Front. Hum. Neurosci. Frontiers in Human Neuroscience Front. Hum. Neurosci. 1662-5161 Frontiers Media S.A. 10.3389/fnhum.2016.00612 Neuroscience Review Ketamine: 50 Years of Modulating the Mind Li Linda 1 Vlisides Phillip E. 2 * 1Department of Internal Medicine, St. Joseph Mercy Hospital Ann Arbor, MI, USA 2Department of Anesthesiology, University of Michigan Medical School Ann Arbor, MI, USA

Edited by: Mikhail Lebedev, Duke University, USA

Reviewed by: Axel Hutt, German Weather Service, Germany; Fabio Sambataro, Fondazione Istituto Italiano di Technologia, Italy; Yingtang Shi, University of Virginia, USA

*Correspondence: Phillip E. Vlisides pvliside@med.umich.edu

 29 11 2016 2016 10 612 06 09 2016 15 11 2016 Copyright © 2016 Li and Vlisides. 2016 Li and Vlisides

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Ketamine was introduced into clinical practice in the 1960s and continues to be both clinically useful and scientifically fascinating. With considerably diverse molecular targets and neurophysiological properties, ketamine’s effects on the central nervous system remain incompletely understood. Investigators have leveraged the unique characteristics of ketamine to explore the invariant, fundamental mechanisms of anesthetic action. Emerging evidence indicates that ketamine-mediated anesthesia may occur via disruption of corticocortical information transfer in a frontal-to-parietal (“top down”) distribution. This proposed mechanism of general anesthesia has since been demonstrated with anesthetics in other pharmacological classes as well. Ketamine remains invaluable to the fields of anesthesiology and critical care medicine, in large part due to its ability to maintain cardiorespiratory stability while providing effective sedation and analgesia. Furthermore, there may be an emerging role for ketamine in treatment of refractory depression and Post-Traumatic Stress Disorder. In this article, we review the history of ketamine, its pharmacology, putative mechanisms of action and current clinical applications.

 ketamine neuropharmacology consciousness anesthesia functional connectivity depression post-traumatic stress disorder T32GM103730 National Institutes of Health10.13039/100000002 Introduction

Fifty years ago, Corssen and Domino (1966) published the first clinical study of ketamine as a human anesthetic. Ketamine produces an unusual state, sometimes referred to as “dissociative anesthesia”, which was a term coined by Domino’s (2010) wife. During this dissociative state, patients might appear awake with preserved airway reflexes and respiratory drive, but they are unable to respond to sensory input (Domino et al., 1965). Ketamine additionally provides excellent analgesia with an impressive safety profile, making it a popular anesthetic induction agent in a variety of patient populations and settings.

Although initially developed as an anesthetic, over the past several decades ketamine has been revealed to have greater potential in the field of medicine. A growing body of literature has demonstrated the clinical value of ketamine across diverse settings, with emerging roles in pain medicine and treatment-resistant depression. Concurrently, efforts to uncover the mechanisms underlying ketamine’s actions are providing researchers with new insights into the relationship between consciousness and anesthesia.

Since the first clinical report in 1966, ketamine has become arguably the most unique anesthetic agent used today and also one of the most promising and exciting in terms of its potential. The purpose of this article is to provide an overview of ketamine’s history, pharmacology, putative mechanisms and clinical applications.

 History

Ketamine’s history begins with phencyclidine, which was first synthesized in 1956 by chemists at Parke Davis Company (Maddox et al., 1965) who discovered ketamine’s unique and fascinating pharmacology. Phencyclidine was capable of causing the appearance of drunkenness in rodents, delirium in dogs, cataleptoid states in pigeons and anesthesia in monkeys (Domino and Luby, 2012). Although demonstrated to be a safe and reliable anesthetic in humans, it also caused an intense, prolonged emergence delirium that ultimately made it undesirable for human use (Greifenstein et al., 1958; Johnstone et al., 1959; Domino and Luby, 2012).

Efforts were subsequently redirected towards synthesizing shorter-acting analogs of phencyclidine that would have similar anesthetic potential but cause less emergence delirium. Ketamine, then identified as CI-581, was one such agent developed by Parke Davis consultant and organic chemist Calvin Stevens in 1962 (Domino, 1980). A structural analog at one-tenth the potency of its parent drug phencyclidine, ketamine was subsequently selected for human trials, and the first human anesthetic dose was administered on August 3, 1964 by two University of Michigan professors: Dr. Edward Domino of Pharmacology (Figure 1) and Dr. Guenter Corssen of Anesthesiology. In their initial pharmacological study of ketamine in 20 humans, Domino and Corssen found evidence that the drug could be safe and effective for clinical anesthetic use (Domino et al., 1965). In 1966, they published findings from the first clinical experiences with ketamine, reporting its anesthetic effects in 130 patients, aged 6 weeks to 86 years, undergoing a total of 133 surgical procedures (Corssen and Domino, 1966). They found that ketamine could rapidly produce profound analgesia with a unique state of altered consciousness and a limited duration of effect that could be safely prolonged with repeated administration. They also reported minimal side effects and a lack of severe emergence delirium compared to phencyclidine (Corssen and Domino, 1966). Ketalar (1970) became the first preparation of ketamine approved by the food and drug administration (FDA) for human use.

Dr. Edward Domino as a young faculty at the University of Michigan. Dr. Domino is now in his 90s, an Emeritus Professor, and still active as a scientist in the field of neuropharmacology. Photograph provided courtesy of the University of Michigan Bentley Historical Library.

 Pharmacology Structure

Ketamine is an arylcycloalkylamine that exists as S(+) and R(−) isomers and is commonly marketed as a racemic mixture of the two (Figure 2). Isolated S(+) ketamine, which is not currently available in the United States but marketed in other parts of the world, has a higher affinity to the binding site on N-methyl-D-aspartate (NMDA)-receptors and produces 3–4 times greater anesthetic potency than the R(−) isomer (White et al., 1985). When used intraoperatively, the S(+) isomer is associated with less cardiac stimulation, less spontaneous motor activity, better analgesia, more rapid recovery, fewer psychotomimetic side effects, and a decreased incidence of emergence delirium (White et al., 1980, 1985). In the more recent use of ketamine as an antidepressant, mouse studies have shown the R(−) isomer to be more potent and with less side effects than the S(+) isomer (Zhang et al., 2014).

Structure of Ketamine.

 Pharmacokinetics and Pharmacodynamics Administration and Bioavailability

Soluble in both water and lipids, ketamine can be safely administered through multiple routes: intravenous (IV), intramuscular (IM), oral, nasal, rectal, subcutaneous and epidural. IV administration is 100% bioavailable and considered the ideal route of administration. However, in certain settings such as emergencies or with uncooperative patients, IM ketamine is commonly used and has only a slightly lower bioavailability of 93% (Clements et al., 1982). A summary of ketamine’s common routes of administration and their respective pharmacologic profiles is provided in Table 1.

Basic pharmacologic profiles of ketamine.

Route Dose* Bioavailability Tmax(minutes) References
IV 1–4.5 mg/kg 100% 3 Weber et al. (2004)
IM 6.5–13 mg/kg 93% 5–10 Clements et al. (1982)
Intranasal 0.5–1 mg/kg 8–45%† 10–20 Yanagihara et al. (2003)
Huge et al. (2010)
Andolfatto et al. (2013)
Yeaman et al. (2014)
PO 0.25–0.5 mg/kg 17–29%† 30 Grant et al. (1981)
Clements et al. (1982)
Chong et al. (2009)
Blonk et al. (2010)
Rolan et al. (2014)
Rectal 9–10 mg/kg 11–25% 30–45 Idvall et al. (1983)
Pedraz et al. (1989)
Malinovsky et al. (1996)

*Dosages may vary depending on clinical setting; anesthetic doses provided per manufacturer labeling for intravenous (IV) and intramuscular (IM) routes. Representative analgesic doses and bioavailability data are outlined for intranasal, oral (PO) and rectal routes. †Intranasal and PO absorption vary significantly. Tmax, time to maximum plasma concentration; mg, milligram; kg, kilogram.

Other routes of administration are less commonly used but exist as feasible options nonetheless. Intraosseous ketamine, for instance, has slightly slower anesthetic onset compared to IV administration (71.3 s and 56.3 s, respectively; Aliman et al., 2011) but may be used in emergency settings. Ketamine can also be administered intranasally, though it has a lower bioavailability of approximately 45% (Yanagihara et al., 2003) and can vary depending on the amount absorbed through nasal mucosa and the amount swallowed. Due to ketamine’s extensive first-pass metabolism, rectal and oral formulations have limited bioavailability with relatively high concentrations of the active (but less-potent) metabolite norketamine (Malinovsky et al., 1996; Chong et al., 2009; Rolan et al., 2014). Historically, these routes are used infrequently in humans, though increasing efforts are being made to develop suitable oral and sublingual formulations given the recent move towards using low-dose ketamine for pain and depression in the outpatient setting (Chong et al., 2009; Rolan et al., 2014).

 Distribution, Metabolism and Excretion

Due to ketamine’s high lipid solubility and relatively limited protein binding, it is rapidly taken up by the brain and redistributed, with a distribution half-life of only 10–15 min (Wieber et al., 1975; Domino et al., 1984). Ketamine has a large volume of distribution of nearly 3 L/kg (Clements and Nimmo, 1981). Once in the body, ketamine undergoes liver metabolism to several metabolites (Clements and Nimmo, 1981). Of note, metabolism through cytochrome systems forms the active metabolite norketamine, which retains anesthetic activity but at one-third the potency of ketamine (Cohen and Trevor, 1974; Domino et al., 1984). Inactive ketamine conjugates and metabolites are renally excreted (Wieber et al., 1975), and elimination half-life is 2–3 h (Domino et al., 1984).

 Dosing

Ketamine’s wide therapeutic range makes it one of the safest anesthetics available. General anesthesia can be induced with both IV and IM routes (Table 1) and maintained with repeated doses of 0.5–1 mg/kg (Domino et al., 1984). Good analgesia and sedation can also be achieved at subanesthetic doses (e.g., 0.2–0.8 mg/kg IV, 2–4 mg/kg IM), and infusions at subanesthetic doses (e.g., 0.5 mg/kg/h) may also provide continuous sedation and analgesia (Allen and Macias, 2005; Miller et al., 2011).

 Systemic Effects Cardiovascular

At both subanesthetic and anesthetic doses, ketamine is predominantly a sympathomimetic, producing increased arterial pressures and heart rate (Corssen and Domino, 1966) through direct stimulation of central nervous system structures (Traber et al., 1970). At higher doses (e.g., 20 mg/kg), however, ketamine also acts as direct myocardial depressant (Traber et al., 1968), and in the setting of compromised autonomic control (e.g., spinal cord transection, catecholamine depletion), these depressive effects may be unmasked. Ketamine also causes direct relaxation of vascular smooth muscle, though due to its sympathetically-mediated vasoconstriction, it has a relatively stable net effect on systemic vascular resistance (Diaz et al., 1976; Akata et al., 2001; Jung and Jung, 2012).

 Pulmonary

Ketamine does not cause clinically significant respiratory depression in patients (Corssen and Domino, 1966), though arterial hypoxemia following rapid IV infusion of ketamine has been reported (Zsigmond et al., 1976). In fact, low-dose ketamine may actually stimulate respiration and is observed to produce higher flow-rates, respiratory rates and duty-cycle (inspiratory time divided by total respiratory cycle time) in animal models (Eikermann et al., 2012). Ketamine is also unique in its ability to preserve upper airway reflexes during anesthesia, uncoupling the loss of consciousness with the loss of upper airway dilator muscle activity (Eikermann et al., 2012). Ketamine further increases genioglossus muscle activity (Eikermann et al., 2012); this elevates and pushes the tongue forward, increasing upper airway diameter to further prevent its collapse (Oliven et al., 2003).

Despite the fact that a patent airway is usually maintained during exposure to ketamine, attention to airway protection remains essential, as partial obstruction and aspiration are still possible. Ketamine may increase salivary secretions (Corssen and Domino, 1966) and potentially increase the risk of laryngospasm, but this is rarely reported (Green et al., 2010). Other respiratory effects of ketamine include bronchodilation, likely through vagolytic and other neurally mediated mechanisms (Brown and Wagner, 1999). At high doses, ketamine may also directly affect airway smooth muscle, but this effect is unlikely to be of clinical importance (Brown and Wagner, 1999).

 Neurological

Because ketamine increases cerebral metabolism, it can potentially increase intracranial pressure (ICP) and has been used cautiously in patients with space-occupying cerebral lesions brain injury (Gardner et al., 1971; Shaprio et al., 1972; Wyte et al., 1972). However, when used in combination with propofol or midazolam, effects on cerebral perfusion are comparable to other commonly used, opioid-based combinations (Bourgoin et al., 2003, 2005; Wang et al., 2014). Ketamine has also been safely used in patients with elevated ICP while helping to maintain optimal hemodynamic profiles (Bourgoin et al., 2003; Schmittner et al., 2007). In fact, in some cases, ketamine’s cerebral effects may be neuroprotective and potentially beneficial for brain trauma patients (Albanèse et al., 1997; Bar-Joseph et al., 2009). This includes ketamine’s inhibition of spreading cortical depolarizations after traumatic brain injury (TBI), an effect that may attenuate the extension of ischemic damage to healthier peri-ischemic tissue (Hertle et al., 2012).

 Side Effects, Toxicities, Interactions and Abuse

Ketamine has multiple dose-dependent side effects, though most of which are self-resolving. Adverse effects include hypersalivation, hyperreflexia and transient clonus (Corssen and Domino, 1966). Ketamine may also cause vestibular-type symptoms including dizziness, nausea and vomiting. Cardiopulmonary toxicity is rare, with effects limited to those caused by the transient sympathetic activation such as tachycardia, hypertension and palpitations (Weiner et al., 2000; Strayer and Nelson, 2008). Given ketamine’s wide therapeutic range, death by overdose is rare and usually involves other intoxicants or in the setting of trauma (Moore et al., 1997; Gill and Stajic, 2000).

The psychoactive properties associated with ketamine limit widespread clinical use. Even at subanesthetic doses (i.e., 0.1–0.4 mg/kg; Krystal et al., 1994), patients may experience perturbing dissociative symptoms. One study described ketamine at such doses producing four main psychological effects (Pomarol-Clotet et al., 2006): (1) a feeling of intoxication, comparable to the effects of other anesthetics and sedatives; (2) perceptual alterations in visual, auditory and somatosensory domains concomitant with symptoms of depersonalization or derealization; (3) referential ideas and delusions, often of misinterpretation and thought disorder; and (4) negative symptoms such as poverty of speech.

More recently, cystitis and various lower urinary tract pathologies (e.g., detrusor over-activity) have also been reported in long-term ketamine users (Chu et al., 2008; Tsai et al., 2009). Ketamine abuse is also associated with gastrointestinal symptoms, including biliary dysfunction, epigastric pain and hepatic injury (Poon et al., 2010; Lo et al., 2011; Wong et al., 2014; Yu et al., 2014), though these adverse effects may be reversible with abstinence (Zhou J. et al., 2013; Wong et al., 2014; Yu et al., 2014).

While ketamine’s psychedelic effects limit clinical use, they have made ketamine a popular recreational drug. At lower doses, stimulant effects predominate, and users experience mild dissociation with hallucinations and a distortion of time and space. Higher doses induce more severe, schizophrenia-like symptoms and perceptions that are completely separate from reality (Wolff and Winstock, 2006; Niesters et al., 2014). Although these effects resolve approximately 2 h after acute ketamine use, long-term use can cause more pronounced and persistent neuropsychiatric symptoms, including schizophrenia-like symptoms, cognitive impairment and poor psychological well-being (Morgan et al., 2009, 2010; Liu et al., 2016).

Finally, given its CNS modulatory activity, ketamine should be used cautiously with other drugs that alter mood and perception, including alcohol, opioids, benzodiazepines and cannabis. Ketamine metabolism involves cytochrome P450 enzymes (Hijazi and Boulieu, 2002), and thus, concomitant use with drugs that inhibit cytochrome P450 metabolism may lead to inhibited ketamine metabolism and supratherapeutic toxicity.

 Proposed Mechanisms of Actions Molecular Targets

Unlike the IV and inhaled anesthetics in common clinical use, ketamine is not thought to act primarily through the potentiation of gamma-aminobutyric acid (GABA) transmission. Early work on the mechanisms of ketamine found that it reduced neuronal excitation by NMDA, the agonist for which the glutamatergic receptor type is named (Anis et al., 1983). Ketamine was found to block excitatory postsynaptic potentials in rat cortical pyramidal cells (Thomson et al., 1985) and frog spinal cord neurons (Martin and Lodge, 1985) in a manner consistent with NMDA antagonism; these data were supported by studies in the central nervous system of the lamprey (Yamamura et al., 1990). Subsequently, mouse models with altered NMDA receptor subunits showed attenuated responses to ketamine (Petrenko et al., 2004; Sato et al., 2004). In fact, ketamine-mediated NMDA receptor antagonism of GABAergic inhibitory interneurons is a postulated mechanism of disinhibition and psychosis (Homayoun and Moghaddam, 2007; Brown et al., 2011).

Ketamine non-competitively antagonizes the NMDA receptor by at least two distinct mechanisms: as an open-channel blocker, binding to a site within the channel pore to occlude the channel and reduce mean open time, and through an allosteric mechanism to decrease channel opening frequency (Orser et al., 1997). Ketamine also has a slow off-rate (86% trapping) and is an example of a high-trapping antagonist of the NMDA receptor, similar to MK-801 (dizocilpine, nearly 100% trapping). Thus, even after glutamate dissociates from the NMDA receptor, ketamine remains trapped in the closed ion channel and causes continued blockade. Conversely, NMDA receptor antagonists with a fast off-rate (low-trapping), such as memantine, (50–70% trapped) escape the channel before it closes, producing less blockade of physiological NMDA function. This results in fewer side effects (e.g., sedative or psychotomimetic) and an NMDA antagonist without “appreciable anesthetic effects” (Sleigh et al., 2014).

In addition to NMDA-antagonism, ketamine acts on a wide-range of other targets, contributing to its unique effects and uses (Table 2). For instance, ketamine’s relaxant effect on airway smooth muscle has been attributed to its inhibition of L-type voltage-dependent Ca2+ channels (Yamakage et al., 1995). Inhibition of calcium channels may also contribute to observed psychodysleptic effects such as dysphoria, psychosis, altered perception and impaired verbal fluency (Baum and Tecson, 1991). A block on monoamine transport systems is also thought to contribute to psychotomimetic and sympathomimetic effects (Nishimura et al., 1998), and recently, a compelling case has been made that hyperpolarization-activated cyclic nucleotide (HCN) channels—sometimes referred to as neuronal pacemaker channels—significantly contribute to ketamine-induced hypnosis (Chen et al., 2009; Zhou C. et al., 2013). These channels may mediate the hypnotic effects of volatile anesthetics as well (Zhou et al., 2015). Although ketamine appears to play a role in opioid potentiation (Finck and Ngai, 1982; Smith et al., 1987; Pacheco et al., 2014), antinociceptive effects mediated by opioid receptors may vary based on receptor subtype (Mikkelsen et al., 1999; Pacheco et al., 2014). Inhibition of serotonin reuptake is another suggested as a mechanism by which ketamine may confer analgesic effects (Martin et al., 1982), and ketamine’s block of large-conductance KCa channels (BK channels) preferentially suppresses spinal microglia hyperactivation after nerve injury and may explain its potent effects on neuropathic pain (Hayashi et al., 2011). More recently, a novel mechanism for activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors by the (R,S)-ketamine metabolite (2S,6S;2R,6R)-hydroxynorketamine has been implicated in the rapid, antidepressant-like properties observed with ketamine (Zanos et al., 2016). Gonadal hormones, such as estrogen and progesterone, may also potentiate the rapidity and potency of ketamine’s antidepressant effects, as demonstrated in preclinical models (Carrier and Kabbaj, 2013; Franceschelli et al., 2015; Hashimoto, 2016). Lastly, ketamine interaction with GABA receptors has been implicated in various clinical pathologies, including obsessive-compulsive disorder (Rodriguez et al., 2015), depression (Perrine et al., 2014) and learning disabilities following chronic exposure (Tan et al., 2011).

Receptor and channel targets of ketamine and related clinical effects.

Antagonism/Inhibition
NMDA receptors • Dissociative anesthesia, amnesia (Oye et al., 1992) • Inhibited sensory perception (Oye et al., 1992) • Analgesia (Oye et al., 1992)
HCN channels • Hypnosis (Chen et al., 2009; Zhou C. et al., 2013)
Calcium channels (L-type voltage-dependent) • Negative cardiac inotropy (Baum and Tecson, 1991) • Airway smooth muscle relaxation (Yamakage et al., 1995)
Voltage-gated sodium channels • Decreased parasympathetic activity (Irnaten et al., 2002) • Local anesthetic effect (Frenkel and Urban, 1992; Haeseler et al., 2003)
BK channels • Analgesic effects on neuropathic pain (Hayashi et al., 2011)
Agonism/Activation
Opioid receptors (particularly μ, δ) • Central antinociception (Finck and Ngai, 1982; Pacheco et al., 2014)
AMPA receptors • Rapid antidepressant effects (Zanos et al., 2016)
GABAA receptors • Anesthetic properties (Irifune et al., 2000)

NMDA, N-methyl-D-aspartate; HCN, Hyperpolarization-activated cyclic nucleotide; BK, Large-conductance potassium channels; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GABAAR, γ-aminobutyric acid A receptor.

Not surprisingly, ketamine’s immediate effects on its various targets cause altered downstream processes. Ketamine’s block of Ca2+ influx through NMDA antagonism may, for instance, lower the activity of protein kinase C (PKC) and other intracellular signals, which could then induce altered protein phosphorylation or signaling. In rodent models, systemic ketamine administration suppresses immediate early gene expression (zif/268, c-fos, junB, fosB, c-jun, junD) in the cortex and hippocampal dentate gyrus after mechanical brain injury (Belluardo et al., 1995). It also decreases NMDA receptor 1 phosphorylation (Mei et al., 2010) and affects mRNA expression implicated in rodent models of hyperalgesia (Ohnesorge et al., 2013). Ketamine acutely increases hippocampal proteins brain-derived neurotrophic factor (BDNF; Garcia et al., 2008; Yang et al., 2013) and mammalian target of rapamycin (mTOR; Yang et al., 2013), which may also help to explain the mechanism for its rapid antidepressant effects. Indeed, investigation into ketamine’s antidepressant effects have led to several reports that ketamine may affect various brain regions through epigenetic mechanisms, such as histone deacetylase modulation (Reus et al., 2013; Choi et al., 2015) and increased BDNF mRNA expression (Duman and Voleti, 2012).

 Systems Neuroscience

At the systems neuroscience level, ketamine’s mechanisms are markedly distinct from drugs such as propofol or the halogenated ethers. Unlike most anesthetics, ketamine does not appear to activate the sleep-promoting ventrolateral preoptic nucleus of the hypothalamus; rather, ketamine activates subcortical wake-promoting nuclei (Lu et al., 2008). This is paralleled in ketamine’s unique neurochemistry. Unlike most other inhaled and IV anesthetics, ketamine increases levels of the arousal-promoting neurotransmitter acetylcholine in the cortex (Pal et al., 2015) and it depends, in part, on noradrenergic transmission for its full effect (Kushikata et al., 2011). Ketamine is the only sedative-hypnotic that maintains or increases thalamic metabolism (Langsjo et al., 2005). Neurophysiologically, ketamine—unlike propofol and sevoflurane—increases electroencephalographic activity around 40 Hz (Lee et al., 2013), but—like other anesthetics—suppresses high gamma activity (Pal et al., 2015) and increases delta power (Lee et al., 2013).

Ketamine is also known to alter neuromodulation of various neurotransmitter systems. It reduces cholinergic neurotransmission by acting as a non-competitive and voltage-dependent inhibitor of nicotinic acetylcholine ion channel receptors, particularly in β1 subunit-containing receptors (Yamakura et al., 2000). It appears to reduce acetylcholine release in the medial pontine reticular formation (mPRF), which may in part explain its ability to alter arousal and breathing (Lydic and Baghdoyan, 2002). Unique to most other anesthetics, ketamine produces stimulatory effects on noradrenergic neurons in the medial prefrontal cortex (mPFC; Kubota et al., 1999), and more recently, it has also been shown to raise ACh levels in the PFC during anesthetic dosing (Pal et al., 2015). Despite increased cholinergic tone in the PFC, however, high-frequency gamma activity and cortical coherence were both suppressed, suggesting that ketamine-induced unconsciousness is characterized by dissociation of cholinergic tone and cortical activation, possibly mediated by suppression of the NMDA receptors on both pyramidal and inhibitory neurons. Thus, with preserved activation of subcortical arousal nuclei and increased cholinergic tone, ketamine-induced loss of consciousness may occur via higher-level mechanisms, as evidenced by fragmented cortical coherence and attention of high-frequency gamma activity (Pal et al., 2015). Disrupted cortical communication and information transfer may in fact be a common mechanism of loss of consciousness across diverse pharmacological classes of anesthetics (Lee et al., 2013), as will be discussed further below.

 Network Connectivity

Despite the differences of ketamine’s actions at the molecular and systems neuroscience levels, there appears to be a common network-level effect that might explain the common functional outcome of lost responsiveness induced by ketamine and the primarily GABAergic anesthetics. Ketamine has been found to functionally disrupt corticocortical connectivity with anesthetic dosing, and this pattern seems to follow a frontal-to-posterior direction (Figure 3; Lee et al., 2013; Blain-Moraes et al., 2014; Schroeder et al., 2016). This frontal-to-posterior disrupted cortical connectivity has been proposed as a mechanism of general anesthesia, having been demonstrated across a broad range of anesthetic drug classes during loss of consciousness (Lee et al., 2013). Previous electroencephalographic studies have used indirect, surrogate measures of information transfer—such as transfer entropy and phase lag index—to demonstrate disrupted connectivity during anesthetic-induced loss of consciousness (Lee et al., 2013; Blain-Moraes et al., 2014). Bonhomme et al. (2016) presented functional MRI data from human volunteers whereby ketamine disrupted cortical connectivity between frontal and posterior cortices, while auditory and visual network integrity was maintained. A recent study used intracranial recordings to demonstrate direct, structural interruption of corticocortical sensory information transfer during ketamine-induced anesthesia in macaque monkeys (Schroeder et al., 2016). During anesthesia, somatosensory information transfer was maintained through thalamocortical pathways, though corticocortical information transfer was inhibited. This study showed direct evidence of inhibited information transfer along structurally connected cortical pathways. Thus, collectively, there is accumulating evidence that ketamine disrupts corticocortical information transfer in the frontal-to-posterior direction while preserving sensory network function during anesthesia. These findings contribute to a higher-order, network-level understanding of the neural correlates of consciousness and also shed further insight into the “dissociative” anesthetic nature of ketamine.

Measures of directed connectivity after induction with Ketamine, adapted from Blain-Moraes et al. (2014). Graphical depiction of dominant feedback connectivity in the waking state that is neutralized after ketamine induction. Please see original article (Blain-Moraes et al., 2014) for additional information.

Subanesthetic ketamine administration has recently been shown to alter functional connectivity patterns as well, with possible mechanistic implications for depression. Wong et al. (2016) found that subanesthetic ketamine administration disrupted functional connectivity between the subgenual anterior cingulate cortex, which is involved with the modulation of mood (Davey et al., 2012), and a network cluster involving the thalamus, hippocampus and the retrosplenial cortex. Using a ketamine infusion dose often used for the treatment of depression, Muthukumaraswamy et al. (2015) demonstrated reduced functional connectivity in frontoparietal networks concomitant with an increase in blissful feelings. Thus, modulation of brain connectivity patterns might also provide a network-level mechanism for ketamine’s effects on depression. As patients in these studies were not reported to lose consciousness, there may be a dose-dependent component to the disruption of functional connectivity.

 Clinical Uses in Medicine

Ketamine has enjoyed expanded clinical relevance since its early development and is now being actively used or explored in a number of clinical fields (Table 3).

Summary of clinical uses for ketamine.

Anesthesia Analgesia and sedation Psychiatry and neuroscience
Advantageous settings: • Hemodynamic instability • Pediatric patients • Uncooperative patients • Traumatic brain injury • Bronchospasm • Battlefield/Mass casualty Acute settings: • Procedures • Burns • ED Agitation/Pain • Post-operative pain Chronic settings: • Cancer pain • CRPS • Phantom limb pain • Fibromyalgia • Ischemic pain • Migraines Emerging use: • Depression • Suicidal ideation • PTSD Modeling: • Schizophrenia • Consciousness

ED, emergency department; CPRS, complex regional pain syndrome; PTSD, post-traumatic stress disorder. Please see text (“Clinical Uses in Medicine” Section) for associated references.

 Anesthesia

Ketamine’s rapid onset, safety, and hemodynamic stability have made it a useful anesthetic induction agent, especially in certain patient populations or settings where its characteristics are particularly advantageous.

Hemodynamic Instability

Ketamine’s effects of sympathetic activation may make it beneficial for use in hemodynamically unstable patients (e.g., traumatic injury, septic shock). In septic patients requiring emergency intubation, ketamine may also be a safer alternative to etomidate, which may cause adrenal insufficiency and is associated with higher in-hospital morbidity in such patient populations (Jabre et al., 2009). However, caution should still be observed, as the cardiac depressant effects may hasten cardiovascular compromise in catecholamine-depleted states (Waxman et al., 1980; Dewhirst et al., 2013).

 Pediatrics

The ability to administer ketamine intramuscularly has made it advantageous for patients in which IV administration may be difficult, including neonates, infants and young children. Together with the ease of administration, efficacy and safety profile in children, ketamine has become one of the most commonly used drugs for procedural sedation and analgesia for children in emergency departments (ED; Haley-Andrews, 2006; Bhargava and Young, 2007). However, anecdotal observations suggest a higher risk of airway complications with ketamine in infants less than 3 months of age (Green and Johnson, 1990; Green et al., 2011), likely due to infant-specific differences in airway reactivity and anatomy rather than ketamine itself. Furthermore, although emergence reactions in children and teenagers are rare and typically mild, risk factors for recovery agitation have emerged. Two clinically pertinent risk factors are: (1) low IM ketamine dosing (<3.0 mg/kg), which may not provide suitable analgesia but still increases agitation; and (2) unusually high IV ketamine dosing (>2.5 mg/kg), which increases the risk of airway complications and emesis (Green et al., 2009). Finally, the use of ketamine as an opioid-sparing agent in children has recently been challenged by a large meta-analysis (Michelet et al., 2016), though this may have been from lack of power given the studies available. Further investigation into ketamine’s effects in children is certainly warranted.

 Traumatic Brain Injury (TBI)

Despite historic concerns that ketamine may cause harmful increases in ICP, recent reports have challenged this with evidence that ketamine can be safely and effectively used in patients with head injuries or risk of intracranial hypertension (Bourgoin et al., 2003, 2005; Wang et al., 2014). In fact, ketamine may have beneficial effects, including protection against seizures, cerebral ischemia or secondary brain injury related to hypotension (Albanèse et al., 1997; Bar-Joseph et al., 2009).

 Bronchospasm

Ketamine’s bronchodilating properties make it an attractive anesthetic induction agent for patients with active bronchospasm. Of note, however, ketamine may predispose patients to laryngospasm through its stimulation of copious secretions, but the incidence of this appears to be relatively rare (Green et al., 2010).

 Trauma Medicine

Upon being marketed as a human anesthetic in the 1970s, ketamine quickly became a popular battlefield anesthetic and continues to be used in military conflict (Mercer, 2009). Its pharmacological properties and ease of administration allow it to be a safe and effective option for anesthetic use in pre-hospital settings, including mass casualty events (Ashkenazi et al., 2005). Moreover, ketamine’s emerging role in affective disorders may have the potential to protect patients in these settings from developing stress-induced disorders (Brachman et al., 2016).

 Analgesia and Sedation

Unlike most other agents, ketamine offers the important advantage of being able to provide both profound analgesia and adequate sedation without significantly compromising airway reflexes or respiratory function (Corssen and Domino, 1966). It is thus often used in acute clinical settings, though there is a growing interest in its role as a chronic therapeutic agent as well.

Acute Setting Procedural sedation

Ketamine is frequently used in the ED for procedural sedation. IM administration has made it an especially popular choice for sedation in children who may otherwise be uncooperative. Although not as frequently used in adults for this purpose due to an increased likelihood of emergence delirium (1–2% in children vs. 10–20% in adults; Strayer and Nelson, 2008), this can effectively be reduced with benzodiazepine administration (Dundee and Lilburn, 1978; Perumal et al., 2015) or with the co-administration of propofol (Willman and Andolfatto, 2007; Andolfatto and Willman, 2010).

 Burn medicine

Historically, ketamine has played a prominent role in burn care protocols, providing effective analgesia and sedation for burn patients who must undergo debridements, grafts, and repeated dressing changes (Demling et al., 1978; Hondorp, 1987; Canpolat et al., 2012; Kundra et al., 2013) without compromising the airway or respiratory function. Furthermore, the ability to administer ketamine intramuscularly and even orally provides an additional advantage in burn patients who have extensive scarring that might make IV administration challenging.

 Acute agitation

Ketamine is also used to treat acutely agitated and violent patients in the ED. Even among agitated patients who are intoxicated, ketamine does not appear to have any major adverse effects on physiological stability (Hopper et al., 2015). However, additional pharmacological treatment is often required in these patients, suggesting that ketamine may be useful only for initial control of severe agitation in this setting (Hopper et al., 2015).

 Acute pain

More recently, low-dose ketamine infusions have been advocated to provide pain relief in the ED. Administering a 15 mg bolus of IV ketamine followed immediately by a continuous infusion at 20 mg/h for 1 h may significantly improve pain scores while maintaining stable vital signs and high patient satisfaction (Ahern et al., 2015).

 Postoperative pain

The use of ketamine infusions has been shown to be an opiate-sparing technique in managing post-operative pain following a variety of surgeries, including abdominal (Guillou et al., 2003; Webb et al., 2007; Zakine et al., 2008; Kaur et al., 2015), thoracic (Michelet et al., 2007; Nesher et al., 2008, 2009; Chazan et al., 2010), orthopedic (Adam et al., 2005; Kollender et al., 2008; Cha et al., 2012; Akhavanakbari et al., 2014), spinal (Kim et al., 2013) and gynecological (Sen et al., 2009; Suppa et al., 2012). However, others have not observed ketamine to have significant clinical benefits or opioid-sparing effects in postoperative pain management (Jensen et al., 2008; Sveticic et al., 2008; Reza et al., 2010; Yeom et al., 2012). These discrepant results may be explained by variation in dosing strategies, patient profiles and other co-administered analgesics.

 Chronic Setting Cancer pain

Ketamine’s potentiation of opioid analgesia and opioid-sparing effect may be useful in cancer patients who otherwise require a high-dose of opioids, although as stated above, there is currently conflicting evidence surrounding ketamine’s effects on opioid requirements. While ketamine’s use as an adjunct analgesic has been demonstrated by randomized control trials (Yang et al., 1996; Mercadante et al., 2000) and smaller studies and case reports (Fine, 1999; Tarumi et al., 2000; Kannan et al., 2002; Amin et al., 2014), the evidence remains inconclusive, as others have not found any net clinical benefit by using ketamine as a part of the analgesic regimen in cancer pain (Hardy et al., 2012; Salas et al., 2012). As above with postoperative pain, inconsistent findings may result from variations in study design.

 Non-cancer pain

Ketamine is increasingly used as an adjunct in treating chronic pain states and appears to provide analgesia through its direct NMDA-receptor antagonism as well as modulation of descending inhibitory paths of pain often implicated in chronic pain states (Niesters et al., 2013). For example, ketamine has been used as an analgesic in patients with complex regional pain syndrome (CPRS: Correll et al., 2004; Finch et al., 2009; Schwartzman et al., 2009; Sigtermans et al., 2009). IV and oral ketamine have also been reported to alleviate symptoms of phantom limb pain (Shanthanna et al., 2010; Mitra and Kazal, 2015), though one case report demonstrated exacerbation of pain after IV ketamine, possibly due to ketamine-induced hallucinations (Sakai and Sumikawa, 2014). Ketamine can also attenuate key mechanisms in fibromyalgia patients, such as muscle and referred pain (Graven-Nielsen et al., 2000); however, these infusions may only provide short-term analgesic relief (Noppers et al., 2011). Ketamine is also an effective analgesic in a variety of chronic pain cases, such as ischemic pain (Liman et al., 2015), migraine with aura (Afridi et al., 2013), breakthrough pain in chronic pain states (Carr et al., 2004), and in patients with developed opioid tolerance or previous opiate abuse (Chazan et al., 2008; Dahi-Taleghani et al., 2014).

 Psychiatric Uses Depression

There has been surging interest in the use of ketamine as a potential therapeutic agent for affective disorders, particularly depression. Even a single-dose of ketamine may cause rapid antidepressant effects in otherwise treatment-resistant cases of bipolar (DiazGranados et al., 2010b; Ibrahim et al., 2011; Kantrowitz et al., 2015) and major depression (Zarate et al., 2006; Murrough et al., 2013). Remarkably, this also includes the acute reduction of suicidal ideation (DiazGranados et al., 2010a; Larkin and Beautrais, 2011; Zigman and Blier, 2013; Murrough et al., 2015). Recent neuroimaging studies support potential anti-anhedonic and anti-depressant effects, demonstrating its ability to alter glucose metabolism in regions implicated in mood disorders (Lally et al., 2014, 2015; Nugent et al., 2014). Repeated ketamine doses may improve depressive symptoms comparable to—and perhaps even more rapidly than—electroconvulsive therapy (ECT; Ghasemi et al., 2014), and it may even be successful in treating ECT-resistant depression (Ibrahim et al., 2011). Despite its observed promising antidepressant effects, however, more rigorous investigation is needed to establish its clinical use as an antidepressant. The current evidence is limited by bias, small sample sizes, and limited data on important cofounding variables. In fact, a recent Cochrane Review determined that the efficacy of ketamine as an antidepressant may be limited beyond 1 week (McCloud et al., 2015).

 Post-Traumatic Stress Disorder (PTSD)

One of the newer applications of ketamine is its role as a potential treatment for Post-Traumatic Stress Disorder (PTSD), although studies examining this remain limited (Feder et al., 2014; Donoghue et al., 2015). For instance, Feder et al. (2014) found that ketamine may reduce symptom severity of PTSD more rapidly than midazolam; however, they did not exclude previously depressed patients, and the observed results may have been due—in part—to ketamine’s known antidepressive effects. A case reported by Donoghue et al. (2015) describing ketamine-induced remission of PTSD and disruptive symptoms in a child similarly provides inconclusive evidence for effects of ketamine specific to PTSD. While it is postulated that ketamine may be useful in preventing the development of PTSD through the induction of stress resilience (Brachman et al., 2016), more research is clearly needed to better define ketamine’s effects on PTSD.

 Models of Schizophrenia

Since its discovery, ketamine has been observed to produce symptoms similar to those of schizophrenia. As a result, researchers have used these drugs extensively as models to study schizophrenia. While it now appears that overlaps in symptoms and even receptor effects are insufficient to explain the complex neuropathology of schizophrenia, ketamine and has undoubtedly facilitated and stimulated research efforts into understanding schizophrenia (Domino and Luby, 2012).

 Conclusions and Future Directions

When the first clinical use of ketamine was reported in 1966 in Anesthesia and Analgesia, it quickly became a popular induction agent among anesthesiologists. Now, 50 years later, ketamine is increasingly being used beyond the operating room, demonstrating clinical utility in the fields of emergency medicine, critical care medicine, pain medicine and psychiatry.

The growing interest of ketamine in a range of settings and patient populations may reflect an impressive benefit-to-risk ratio. Unique compared to other anesthetic agents, ketamine produces potent anesthesia, sedation and analgesia while maintaining cardiopulmonary stability and airway patency. Ketamine offers flexible options for administration, and the adverse psychological effects are often transient and either prevented by or alleviated with premedication or combined use with other agents. Nonetheless, the psychoactive effects often remain the limiting factor for its expanded clinical use, and just as ketamine was originally developed to reduce the emergence delirium that prevented phencyclidine’s use in humans, researchers have now moved towards developing shorter acting analogs of ketamine to further reduce the psychogenic effects (Harvey et al., 2015).

Scientifically, investigators have taken advantage of ketamine’s complex molecular and neurophysiological mechanisms of action to gain further insights into the neural correlates of consciousness. Ketamine appears to inhibit information transfer in cortical networks (Bonhomme et al., 2016; Schroeder et al., 2016), which may be a shared mechanism by which diverse anesthetics induce unconsciousness (Lee et al., 2013). Perturbations in cortical network connectivity also correlate with pathological brain states, such as depression (Muthukumaraswamy et al., 2015; Nugent et al., 2016), and ketamine-induced alterations in connectivity patterns may subserve its antidepressant effects (Muthukumaraswamy et al., 2015; Nugent et al., 2016). Indeed, ketamine is being used as a tool for probing the mind to further inform our neurobiological framework of consciousness and altered brain states, and lines of investigation are actively ongoing (Mashour, 2016).

Over the past 50 years, countless patients have benefited greatly from ketamine. We anticipate many more exciting discoveries in the next 50 years of investigating its clinical applications and mechanisms of modulating the mind.

 Author Contributions

Both authors contributed to the writing of the manuscript, approved the final version to be published, and are accountable for manuscript accuracy and integrity. LL: conception, design and drafting of the initial manuscript. PEV: critical manuscript review and revision of all final content.

 Funding

PEV is supported by the National Institutes of Health, Bethesda, MD, USA, Grant T32GM103730. Funding also provided by the Department of Anesthesiology, University of Michigan Medical School.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to acknowledge support from the Department of Anesthesiology at the University of Michigan Medical School. Additionally, the authors would like to thank Dr. George Mashour for expert consultation throughout the manuscript writing process.

 References Adam F. Chauvin M. Du Manoir B. Langlois M. Sessler D. I. Fletcher D. (2005). Small-dose ketamine infusion improves postoperative analgesia and rehabilitation after total knee arthroplasty. Anesth. Analg. 100, 475–480. doi: 10.1213/01.ane.0000142117.82241.dc15673878 Afridi S. K. Giffin N. J. Kaube H. Goadsby P. J. (2013). A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80, 642–647. doi: 10.1212/wnl.0b013e3182824e6623365053 Ahern T. L. Herring A. A. Miller S. Frazee B. W. (2015). Low-Dose ketamine infusion for emergency department patients with severe pain. Pain Med. 16, 1402–1409. doi: 10.1111/pme.1270525643741 Akata T. Izumi K. Nakashima M. (2001). Mechanisms of direct inhibitory action of ketamine on vascular smooth muscle in mesenteric resistance arteries. Anesthesiology 95, 452–462. doi: 10.1097/00000542-200108000-0003011506120 Akhavanakbari G. Mohamadian A. Entezariasl M. (2014). Evaluation the effects of adding ketamine to morphine in intravenous patient-controlled analgesia after orthopedic surgery. Perspect. Clin. Res. 5, 85–87. doi: 10.4103/2229-3485.12802824741486 Albanèse J. Arnaud S. Rey M. Thomachot L. Alliez B. Martin C. (1997). Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology 87, 1328–1334. doi: 10.1097/00000542-199712000-000119416717 Aliman A. C. Piccioni M. A. Piccioni J. L. Oliva J. L. Auler Júnior J. O. (2011). Intraosseous anesthesia in hemodynamic studies in children with cardiopathy. Rev. Bras. Anestesiol. 61, 41–49. doi: 10.1016/s0034-7094(11)70005-821334506 Allen J. Y. Macias C. G. (2005). The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann. Emerg. Med. 46, 43–50. doi: 10.1016/j.annemergmed.2005.02.02415988425 Amin P. Roeland E. Atayee R. (2014). Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain. J. Pain Palliat. Care Pharmacother. 28, 233–242. doi: 10.3109/15360288.2014.93888125102039 Andolfatto G. Willman E. (2010). A prospective case series of pediatric procedural sedation and analgesia in the emergency department using single-syringe ketamine-propofol combination (ketofol). Acad. Emerg. Med. 17, 194–201. doi: 10.1111/j.1553-2712.2009.00646.x20370749 Andolfatto G. Willman E. Joo D. Miller P. Wong W. B. Koehn M. . (2013). Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad. Emerg. Med. 20, 1050–1054. doi: 10.1111/acem.1222924127709 Anis N. A. Berry S. C. Burton N. R. Lodge D. (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79, 565–575. doi: 10.1111/j.1476-5381.1983.tb11031.x6317114 Ashkenazi I. Isakovich B. Kluger Y. Alfici R. Kessel B. Better O. S. (2005). Prehospital management of earthquake casualties buried under rubble. Prehosp. Disaster Med. 20, 122–133. doi: 10.1017/s1049023x0000230215898492 Bar-Joseph G. Guilburd Y. Tamir A. Guilburd J. N. (2009). Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension. J. Neurosurg. Pediatr. 4, 40–46. doi: 10.3171/2009.1.PEDS0831919569909 Baum V. C. Tecson M. E. (1991). Ketamine inhibits transsarcolemmal calcium entry in guinea pig myocardium: direct evidence by single cell voltage clamp. Anesth. Analg. 73, 804–807. doi: 10.1213/00000539-199112000-000221952182 Belluardo N. Mudò G. Dell’Albani P. Jiang X. H. Condorelli D. F. (1995). NMDA receptor-dependent and -independent immediate early gene expression induced by focal mechanical brain injury. Neurochem. Int. 26, 443–453. doi: 10.1016/0197-0186(94)00155-n7492942 Bhargava R. Young K. D. (2007). Procedural pain management patterns in academic pediatric emergency departments. Acad. Emerg. Med. 14, 479–482. doi: 10.1197/j.aem.2006.12.00617363765 Blain-Moraes S. Lee U. Ku S. Noh G. Mashour G. A. (2014). Electroencephalographic effects of ketamine on power, cross-frequency coupling and connectivity in the alpha bandwidth. Front. Syst. Neurosci. 8:114. doi: 10.3389/fnsys.2014.0011425071473 Blonk M. I. Koder B. G. van den Bemt P. M. Huygen F. J. (2010). Use of oral ketamine in chronic pain management: a review. Eur. J. Pain 14, 466–472. doi: 10.1016/j.ejpain.2009.09.00519879174 Bonhomme V. Vanhaudenhuyse A. Demertzi A. Bruno M. A. Jaquet O. Bahri M. A. . (2016). Resting-state network-specific breakdown of functional connectivity during ketamine alteration of consciousness in volunteers. Anesthesiology 125, 873–888. doi: 10.1097/aln.000000000000127527496657 Bourgoin A. Albanèse J. Léone M. Sampol-Manos E. Viviand X. Martin C. (2005). Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. Crit. Care Med. 33, 1109–1113. doi: 10.1097/01.ccm.0000162491.26292.9815891344 Bourgoin A. Albanèse J. Wereszczynski N. Charbit M. Vialet R. Martin C. (2003). Safety of sedation with ketamine in severe head injury patients: comparison with sufentanil. Crit. Care Med. 31, 711–717. doi: 10.1097/01.ccm.0000044505.24727.1612626974 Brachman R. A. McGowan J. C. Perusini J. N. Lim S. C. Pham T. H. Faye C. . (2016). Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol. Psychiatry 79, 776–786. doi: 10.1016/j.biopsych.2015.04.02226037911 Brown E. N. Purdon P. L. Van Dort C. J. (2011). General anesthesia and altered states of arousal: a systems neuroscience analysis. Annu. Rev. Neurosci. 34, 601–628. doi: 10.1146/annurev-neuro-060909-15320021513454 Brown R. H. Wagner E. M. (1999). Mechanisms of bronchoprotection by anesthetic induction agents: propofol versus ketamine. Anesthesiology 90, 822–828. doi: 10.1097/00000542-199903000-0002510078684 Canpolat D. G. Esmaoglu A. Tosun Z. Akn A. Boyaci A. Coruh A. (2012). Ketamine-propofol vs. ketamine-dexmedetomidine combinations in pediatric patients undergoing burn dressing changes. J. Burn Care Res. 33, 718–722. doi: 10.1097/BCR.0b013e318250431622878491 Carr D. B. Goudas L. C. Denman W. T. Brookoff D. Staats P. S. Brennen L. . (2004). Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 108, 17–27. doi: 10.1016/j.pain.2003.07.00115109503 Carrier N. Kabbaj M. (2013). Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70, 27–34. doi: 10.1016/j.neuropharm.2012.12.00923337256 Cha M. H. Eom J. H. Lee Y. S. Kim W. Y. Park Y. C. Min S. H. . (2012). Beneficial effects of adding ketamine to intravenous patient-controlled analgesia with fentanyl after the Nuss procedure in pediatric patients. Yonsei Med. J. 53, 427–432. doi: 10.3349/ymj.2012.53.2.42722318834 Chazan S. Buda I. Nesher N. Paz J. Weinbroum A. A. (2010). Low-dose ketamine via intravenous patient-controlled analgesia device after various transthoracic procedures improves analgesia and patient and family satisfaction. Pain Manag. Nurs. 11, 169–176. doi: 10.1016/j.pmn.2009.06.00320728066 Chazan S. Ekstein M. P. Marouani N. Weinbroum A. A. (2008). Ketamine for acute and subacute pain in opioid-tolerant patients. J. Opioid Manag. 4, 173–180. 18717513 Chen X. Shu S. Bayliss D. A. (2009). HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J. Neurosci. 29, 600–609. doi: 10.1523/JNEUROSCI.3481-08.200919158287 Choi M. Lee S. H. Wang S. E. Ko S. Y. Song M. Choi J. S. . (2015). Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats. Proc. Natl. Acad. Sci. U S A 112, 15755–15760. doi: 10.1073/pnas.151391311226647181 Chong C. Schug S. A. Page-Sharp M. Jenkins B. Ilett K. F. (2009). Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin. Drug Investig. 29, 317–324. doi: 10.2165/00044011-200929050-0000419366273 Chu P. S. Ma W. K. Wong S. C. Chu R. W. Cheng C. H. Wong S. . (2008). The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 102, 1616–1622. doi: 10.1111/j.1464-410X.2008.07920.x18680495 Clements J. A. Nimmo W. S. (1981). Pharmacokinetics and analgesic effect of ketamine in man. Br. J. Anaesth. 53, 27–30. doi: 10.1093/bja/53.1.277459184 Clements J. A. Nimmo W. S. Grant I. S. (1982). Bioavailability, pharmacokinetics and analgesic activity of ketamine in humans. J. Pharm. Sci. 71, 539–542. doi: 10.1002/jps.26007105167097501 Cohen M. L. Trevor A. J. (1974). On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J. Pharmacol. Exp. Ther. 189, 351–358. 4829218 Correll G. E. Maleki J. Gracely E. J. Muir J. J. Harbut R. E. (2004). Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 5, 263–275. doi: 10.1111/j.1526-4637.2004.04043.x15367304 Corssen G. Domino E. F. (1966). Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth. Analg. 45, 29–40. doi: 10.1213/00000539-196601000-000075325977 Dahi-Taleghani M. Fazli B. Ghasemi M. Vosoughian M. Dabbagh A. (2014). Effect of intravenous patient controlled ketamine analgesiaon postoperative pain in opium abusers. Anesth. Pain Med. 4:e14129. doi: 10.5812/aapm.1412924701419 Davey C. G. Harrison B. J. Yücel M. Allen N. B. (2012). Regionally specific alterations in functional connectivity of the anterior cingulate cortex in major depressive disorder. Psychol. Med. 42, 2071–2081. doi: 10.1017/s003329171200032323346586 Demling R. H. Ellerbe S. Jarrett F. (1978). Ketamine anesthesia for tangenital excision of burn eschar: a burn unit procedure. J. Trauma 18, 269–270. doi: 10.1097/00005373-197804000-00009660673 Dewhirst E. Frazier W. J. Leder M. Fraser D. D. Tobias J. D. (2013). Cardiac arrest following ketamine administration for rapid sequence intubation. J. Intensive Care Med. 28, 375–379. doi: 10.1177/088506661244873222644454 Diaz F. A. Bianco J. A. Bello A. Beer N. Velarde H. Izquierdo J. P. . (1976). Effects of ketamine on canine cardiovascular function. Br. J. Anaesth. 48, 941–946. doi: 10.1093/bja/48.10.941990147 DiazGranados N. Ibrahim L. A. Brutsche N. E. Ameli R. Henter I. D. Luckenbaugh D. A. . (2010a). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71, 1605–1611. doi: 10.4088/jcp.09m05327blu20673547 DiazGranados N. Ibrahim L. Brutsche N. E. Newberg A. Kronstein P. Khalife S. . (2010b). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793–802. doi: 10.1001/archgenpsychiatry.2010.9020679587 Domino E. F. (1980). History and pharmacology of PCP and PCP-related analogs. J. Psychedelic Drugs 12, 223–227. doi: 10.1080/02791072.1980.104714307431418 Domino E. F. (2010). Taming the ketamine tiger. 1965. Anesthesiology 113, 678–684. doi: 10.1097/aln.0b013e3181ed09a220693870 Domino E. F. Chodoff P. Corssen G. (1965). Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6, 279–291. doi: 10.1002/cpt19656327914296024 Domino E. F. Domino S. E. Smith R. E. Domino L. E. Goulet J. R. Domino K. E. . (1984). Ketamine kinetics in unmedicated and diazepam-premedicated subjects. Clin. Pharmacol. Ther. 36, 645–653. doi: 10.1038/clpt.1984.2356488686 Domino E. F. Luby E. D. (2012). Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr. Bull. 38, 914–919. doi: 10.1093/schbul/sbs01122390879 Donoghue A. C. Roback M. G. Cullen K. R. (2015). Remission from behavioral dysregulation in a child with PTSD after receiving procedural ketamine. Pediatrics 136, e694–e696. doi: 10.1542/peds.2014-415226260717 Duman R. S. Voleti B. (2012). Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 35, 47–56. doi: 10.1016/j.tins.2011.11.00422217452 Dundee J. W. Lilburn J. K. (1978). Ketamine-iorazepam. Attenuation of psychic sequelae of ketamine by lorazepam. Anaesthesia 33, 312–314. doi: 10.1111/j.1365-2044.1978.tb12413.x27121 Eikermann M. Grosse-Sundrup M. Zaremba S. Henry M. E. Bittner E. A. Hoffmann U. . (2012). Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. Anesthesiology 116, 35–46. doi: 10.1097/aln.0b013e31823d010a22108392 Feder A. Parides M. K. Murrough J. W. Perez A. M. Morgan J. E. Saxena S. . (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71, 681–688. doi: 10.1001/jamapsychiatry.2014.6224740528 Finch P. M. Knudsen L. Drummond P. D. (2009). Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain 146, 18–25. doi: 10.1016/j.pain.2009.05.01719703730 Finck A. D. Ngai S. H. (1982). Opiate receptor mediation of ketamine analgesia. Anesthesiology 56, 291–297. doi: 10.1097/00000542-198204000-000116278991 Fine P. G. (1999). Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J. Pain Symptom Manage. 17, 296–300. doi: 10.1016/s0885-3924(98)00144-410203883 Franceschelli A. Sens J. Herchick S. Thelen C. Pitychoutis P. M. (2015). Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naive and “depressed” mice exposed to chronic mild stress. Neuroscience 290, 49–60. doi: 10.1016/j.neuroscience.2015.01.00825595985 Frenkel C. Urban B. W. (1992). Molecular actions of racemic ketamine on human CNS sodium channels. Br. J. Anaesth. 69, 292–297. doi: 10.1093/bja/69.3.2921327042 Garcia L. S. Comim C. M. Valvassori S. S. Réus G. Z. Barbosa L. M. Andreazza A. C. . (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 140–144. doi: 10.1016/j.pnpbp.2007.07.02717884272 Gardner A. E. Olson B. E. Lichtiger M. (1971). Cerebrospinal-fluid pressure during dissociative anesthesia with ketamine. Anesthesiology 35, 226–228. doi: 10.1097/00000542-197108000-000295568142 Ghasemi M. Kazemi M. H. Yoosefi A. Ghasemi A. Paragomi P. Amini H. . (2014). Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 215, 355–361. doi: 10.1016/j.psychres.2013.12.00824374115 Gill J. R. Stajic M. (2000). Ketamine in non-hospital and hospital deaths in New York City. J. Forensic Sci. 45, 655–658. doi: 10.1520/jfs14742j10855972 Grant I. S. Nimmo W. S. Clements J. A. (1981). Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br. J. Anaesth. 53, 805–810. doi: 10.1093/bja/53.8.8057272143 Graven-Nielsen T. Aspegren Kendall S. Henriksson K. G. Bengtsson M. Sörensen J. Johnson A. . (2000). Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain 85, 483–491. doi: 10.1016/s0304-3959(99)00308-510781923 Green S. M. Johnson N. E. (1990). Ketamine sedation for pediatric procedures: part 2, review and implications. Ann. Emerg. Med. 19, 1033–1046. doi: 10.1016/s0196-0644(05)82569-72203290 Green S. M. Roback M. G. Krauss B. Brown L. McGlone R. G. Agrawal D. . (2009). Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children. Ann. Emerg. Med. 54, 171.e4–180.e4. doi: 10.1016/j.annemergmed.2009.04.00419501426 Green S. M. Roback M. G. Krauss B. Emergency Department Ketamine Meta-Analysis Study Group. (2010). Laryngospasm during emergency department ketamine sedation: a case-control study. Pediatr. Emerg. Care 26, 798–802. doi: 10.1097/PEC.0b013e3181fa873720944510 Green S. M. Roback M. G. Kennedy R. M. Krauss B. (2011). Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann. Emerg. Med. 57, 449–461. doi: 10.1016/j.annemergmed.2010.11.03021256625 Greifenstein F. E. Devault M. Yoshitake J. Gajewski J. E. (1958). A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth. Analg. 37, 283–294. doi: 10.1213/00000539-195809000-0000713583607 Guillou N. Tanguy M. Seguin P. Branger B. Campion J. P. Malledant Y. (2003). The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth. Analg. 97, 843–847. doi: 10.1213/01.ane.0000075837.67275.3612933413 Haeseler G. Tetzlaff D. Bufler J. Dengler R. Münte S. Hecker H. . (2003). Blockade of voltage-operated neuronal and skeletal muscle sodium channels by S+- and R--ketamine. Anesth. Analg. 96, 1019–1026. doi: 10.1213/01.ane.0000052513.91900.d512651652 Haley-Andrews S. (2006). Ketamine: the sedative of choice in a busy pediatric emergency department. J. Emerg. Nurs. 32, 186–188. doi: 10.1016/j.jen.2005.12.05116580488 Hardy J. Quinn S. Fazekas B. Plummer J. Eckermann S. Agar M. . (2012). Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J. Clin. Oncol. 30, 3611–3617. doi: 10.1200/JCO.2012.42.108122965960 Harvey M. Sleigh J. Voss L. Jose J. Gamage S. Pruijn F. . (2015). Development of rapidly metabolized and ultra-short-acting ketamine analogs. Anesth. Analg. 121, 925–933. doi: 10.1213/ANE.000000000000071925822925 Hashimoto K. (2016). Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin. Ther. Targets 20, 1389–1392. doi: 10.1080/14728222.2016.123889927646666 Hayashi Y. Kawaji K. Sun L. Zhang X. Koyano K. Yokoyama T. . (2011). Microglial Ca2+-activated K+ channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain. J. Neurosci. 31, 17370–17382. doi: 10.1523/JNEUROSCI.4152-11.201122131399 Hertle D. N. Dreier J. P. Woitzik J. Hartings J. A. Bullock R. Okonkwo D. O. . (2012). Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain 135, 2390–2398. doi: 10.1093/brain/aws15222719001 Hijazi Y. Boulieu R. (2002). Contribution of CYP3A4, CYP2B6 and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 30, 853–858. doi: 10.1124/dmd.30.7.85312065445 Homayoun H. Moghaddam B. (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496–11500. doi: 10.1523/JNEUROSCI.2213-07.200717959792 Hondorp M. (1987). Burn care protocols: administration of ketamine. Feature protocol San Francisco general hospital, San Francisco, California. J. Burn Care Rehabil. 8, 148–149. doi: 10.1097/00004630-198703000-000163647044 Hopper A. B. Vilke G. M. Castillo E. M. Campillo A. Davie T. Wilson M. P. (2015). Ketamine use for acute agitation in the emergency department. J. Emerg. Med. 48, 712–719. doi: 10.1016/j.jemermed.2015.02.01925843924 Huge V. Lauchart M. Magerl W. Schelling G. Beyer A. Thieme D. . (2010). Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur. J. Pain 14, 387–394. doi: 10.1016/j.ejpain.2009.08.00219733106 Ibrahim L. Diazgranados N. Luckenbaugh D. A. Machado-Vieira R. Baumann J. Mallinger A. G. . (2011). Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1155–1159. doi: 10.1016/j.pnpbp.2011.03.01921466832 Idvall J. Holasek J. Stenberg P. (1983). Rectal ketamine for induction of anaesthesia in children. Anaesthesia 38, 60–64. doi: 10.1111/j.1365-2044.1983.tb14159.x6824156 Irifune M. Sato T. Kamata Y. Nishikawa T. Dohi T. Kawahara M. (2000). Evidence for GABA(A) receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth. Analg. 91, 230–236. doi: 10.1097/00000539-200007000-0004310866918 Irnaten M. Wang J. Chang K. S. Andresen M. C. Mendelowitz D. (2002). Ketamine inhibits sodium currents in identified cardiac parasympathetic neurons in nucleus ambiguus. Anesthesiology 96, 659–666. doi: 10.1097/00000542-200203000-0002311873042 Jabre P. Combes X. Lapostolle F. Dhaouadi M. Ricard-Hibon A. Vivien B. . (2009). Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 374, 293–300. doi: 10.1016/S0140-6736(09)60949-119573904 Jensen L. L. Handberg G. Helbo-Hansen H. S. Skaarup I. Lohse T. Munk T. . (2008). No morphine sparing effect of ketamine added to morphine for patient-controlled intravenous analgesia after uterine artery embolization. Acta Anaesthesiol. Scand. 52, 479–486. doi: 10.1111/j.1399-6576.2008.01602.x18339153 Johnstone M. Evans V. Baigel S. (1959). Sernyl (CI-395) in clinical anaesthesia. Br. J. Anaesth. 31, 433–439. doi: 10.1093/bja/31.10.43314407580 Jung I. Jung S. H. (2012). Vasorelaxant mechanisms of ketamine in rabbit renal artery. Korean J. Anesthesiol. 63, 533–539. doi: 10.4097/kjae.2012.63.6.53323277815 Kannan T. R. Saxena A. Bhatnagar S. Barry A. (2002). Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J. Pain Symptom. Manage. 23, 60–65. doi: 10.1016/s0885-3924(01)00373-611779670 Kantrowitz J. T. Halberstam B. Gangwisch J. (2015). Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J. Clin. Psychiatry 76, 737–738. doi: 10.4088/JCP.14l0952726132675 Kaur S. Saroa R. Aggarwal S. (2015). Effect of intraoperative infusion of low-dose ketamine on management of postoperative analgesia. J. Nat. Sci. Biol. Med. 6, 378–382. doi: 10.4103/0976-9668.16001226283834 Ketalar (1970). “U.S. food and drug administration, center for drug evaluation and research,” in Label and Approval History. Available online at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist 11665545 Kim S. H. Kim S. I. Ok S. Y. Park S. Y. Kim M. G. Lee S. J. . (2013). Opioid sparing effect of low dose ketamine in patients with intravenous patient-controlled analgesia using fentanyl after lumbar spinal fusion surgery. Korean J. Anesthesiol. 64, 524–528. doi: 10.4097/kjae.2013.64.6.52423814653 Kollender Y. Bickels J. Stocki D. Maruoani N. Chazan S. Nirkin A. . (2008). Subanaesthetic ketamine spares postoperative morphine and controls pain better than standard morphine does alone in orthopaedic-oncological patients. Eur. J. Cancer 44, 954–962. doi: 10.1016/j.ejca.2008.02.02118396035 Krystal J. H. Karper L. P. Seibyl J. P. Freeman G. K. Delaney R. Bremner J. D. . (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199–214. doi: 10.1001/archpsyc.1994.039500300350048122957 Kubota T. Anzawa N. Hirota K. Yoshida H. Kushikata T. Matsuki A. (1999). Effects of ketamine and pentobarbital on noradrenaline release from the medial prefrontal cortex in rats. Can. J. Anaesth. 46, 388–392. doi: 10.1007/bf0301323510232727 Kundra P. Velayudhan S. Krishnamachari S. Gupta S. L. (2013). Oral ketamine and dexmedetomidine in adults’ burns wound dressing—A randomized double blind cross over study. Burns 39, 1150–1156. doi: 10.1016/j.burns.2013.02.01223623339 Kushikata T. Yoshida H. Kudo M. Kudo T. Kudo T. Hirota K. (2011). Role of coerulean noradrenergic neurones in general anaesthesia in rats. Br. J. Anaesth. 107, 924–929. doi: 10.1093/bja/aer30321965049 Lally N. Nugent A. C. Luckenbaugh D. A. Ameli R. Roiser J. P. Zarate C. A. (2014). Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4:e469. doi: 10.1038/tp.2014.10525313512 Lally N. Nugent A. C. Luckenbaugh D. A. Niciu M. J. Roiser J. P. Zarate C. A. Jr. (2015). Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J. Psychopharmacol. 29, 596–607. doi: 10.1177/026988111456804125691504 Langsjo J. W. Maksimow A. Salmi E. Kaisti K. Aalto S. Oikonen V. . (2005). S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 103, 258–268. doi: 10.1097/00000542-200508000-0000816052107 Larkin G. L. Beautrais A. L. (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 14, 1127–1131. doi: 10.1017/S146114571100062921557878 Lee U. Ku S. Noh G. Baek S. Choi B. Mashour G. A. (2013). Disruption of frontal–parietal communication by ketamine, propofol and sevoflurane. Anesthesiology 118, 1264–1275. doi: 10.1097/ALN.0b013e31829103f523695090 Liman S. Cheung C. W. Wong K. L. Tai W. Qiu Q. Ng K. F. . (2015). Preventive treatment with ketamine attenuates the ischaemia-reperfusion response in a chronic postischaemia pain model. Oxid. Med. Cell. Longev. 2015:380403. doi: 10.1155/2015/38040326161236 Liu Y. Lin D. Wu B. Zhou W. (2016). Ketamine abuse potential and use disorder. Brain Res. Bull. 126, 68–73. doi: 10.1016/j.brainresbull.2016.05.01627261367 Lo R. S. Krishnamoorthy R. Freeman J. G. Austin A. S. (2011). Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med. J. 52, e52–e55. 21451916 Lu J. Nelson L. E. Franks N. Maze M. Chamberlin N. L. Saper C. B. (2008). Role of endogenous sleep-wake and analgesic systems in anesthesia. J. Comp. Neurol. 508, 648–662. doi: 10.1002/cne.2168518383504 Lydic R. Baghdoyan H. A. (2002). Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing and disrupt sleep. Sleep 25, 617–622. 12224840 Maddox V. H. Godefroi E. F. Parcell R. F. (1965). The synthesis of phencyclidine and other 1-arylcyclohexylamines. J. Med. Chem. 8, 230–235. doi: 10.1021/jm00326a01914332667 Malinovsky J. M. Servin F. Cozian A. Lepage J. Y. Pinaud M. (1996). Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br. J. Anaesth. 77, 203–207. doi: 10.1093/bja/77.2.2038881626 Martin L. L. Bouchal R. L. Smith D. J. (1982). Ketamine inhibits serotonin uptake in vivo. Neuropharmacology 21, 113–118. doi: 10.1016/0028-3908(82)90149-66460944 Martin D. Lodge D. (1985). Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 24, 999–1003. doi: 10.1016/0028-3908(85)90128-52866465 Mashour G. A. (2016). Network-level mechanisms of ketamine anesthesia. Anesthesiology 125, 830–831. doi: 10.1097/ALN.000000000000127627483123 Mei X. P. Wang W. Wang W. Zhu C. Chen L. Zhang T. . (2010). Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain ketamine, astrocytic inhibitor and pain. Mol. Pain 6:50. doi: 10.1186/1744-8069-6-5020815929 Mercadante S. Arcuri E. Tirelli W. Casuccio A. (2000). Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J. Pain Symptom. Manage. 20, 246–252. doi: 10.1016/S0885-3924(00)00194-911027905 Mercer S. J. (2009). ‘The drug of war’–a historical review of the use of Ketamine in military conflicts. J. R. Nav. Med. Serv. 95, 145–150. 20180434 McCloud T. L. Caddy C. Jochim J. Rendell J. M. Diamond P.R. Shuttleworth C. . (2015). Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst. Rev. 9:CD011612. doi: 10.1002/14651858.CD011611.pub226415966 Michelet P. Guervilly C. Hélaine A. Avaro J. P. Blayac D. Gaillat F. . (2007). Adding ketamine to morphine for patient-controlled analgesia after thoracic surgery: influence on morphine consumption, respiratory function and nocturnal desaturation. Br. J. Anaesth. 99, 396–403. doi: 10.1093/bja/aem16817576969 Michelet D. Hilly J. Skhiri A. Abdat R. Diallo T. Brasher C. . (2016). Opioid-sparing effect of ketamine in children: a meta-analysis and trial sequential analysis of published studies. Paediatr. Drugs [Epub ahead of print]. doi: 10.1007/s40272-016-0196-y27688125 Mikkelsen S. Ilkjaer S. Brennum J. Borgbjerg F. M. Dahl J. B. (1999). The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology 90, 1539–1545. doi: 10.1097/00000542-199906000-0000710360849 Miller A. C. Jamin C. T. Elamin E. M. (2011). Continuous intravenous infusion of ketamine for maintenance sedation. Minerva Anestesiol. 77, 812–820. 21730929 Mitra S. Kazal S. (2015). Oral ketamine for phantom limb pain: an option for challenging cases. Indian J. Anaesth. 59, 446–448. doi: 10.4103/0019-5049.16096326257422 Moore K. A. Kilbane E. M. Jones R. Kunsman G. W. Levine B. Smith M. (1997). Tissue distribution of ketamine in a mixed drug fatality. J. Forensic Sci. 42, 1183–1185. doi: 10.1520/jfs14283j9397567 Morgan C. J. Muetzelfeldt L. Curran H. V. (2009). Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104, 77–87. doi: 10.1111/j.1360-0443.2008.02394.x19133891 Morgan C. J. Muetzelfeldt L. Curran H. V. (2010). Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105, 121–133. doi: 10.1111/j.1360-0443.2009.02761.x19919593 Murrough J. W. Iosifescu D. V. Chang L. C. Al Jurdi R. K. Green C. E. Perez A. M. . (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170, 1134–1142. doi: 10.1176/appi.ajp.2013.1303039223982301 Murrough J. W. Soleimani L. DeWilde K. E. Collins K. A. Lapidus K. A. Iacoviello B. M. . (2015). Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med. 45, 3571–3580. doi: 10.1017/S003329171500150626266877 Muthukumaraswamy S. D. Shaw A. D. Jackson L. E. Hall J. Moran R. Saxena N. (2015). Evidence that subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans. J. Neurosci. 35, 11694–11706. doi: 10.1523/JNEUROSCI.0903-15.201526290246 Nesher N. Ekstein M. P. Paz Y. Marouani N. Chazan S. Weinbroum A. A. (2009). Morphine with adjuvant ketamine vs. higher dose of morphine alone for immediate postthoracotomy analgesia. Chest 136, 245–252. doi: 10.1378/chest.08-024618753471 Nesher N. Serovian I. Marouani N. Chazan S. Weinbroum A. A. (2008). Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. Pharmacol. Res. 58, 38–44. doi: 10.1016/j.phrs.2008.06.00318602474 Niesters M. Aarts L. Sarton E. Dahan A. (2013). Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study. Br. J. Anaesth. 110, 1010–1016. doi: 10.1093/bja/aes57823384733 Niesters M. Martini C. Dahan A. (2014). Ketamine for chronic pain: risks and benefits. Br. J. Clin. Pharmacol. 77, 357–367. doi: 10.1111/bcp.1209423432384 Nishimura M. Sato K. Okada T. Yoshiya I. Schloss P. Shimada S. . (1998). Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88, 768–774. doi: 10.1097/00000542-199803000-000299523822 Noppers I. Niesters M. Swartjes M. Bauer M. Aarts L. Geleijnse N. . (2011). Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur. J. Pain 15, 942–949. doi: 10.1016/j.ejpain.2011.03.00821482474 Nugent A. C. Diazgranados N. Carlson P. J. Ibrahim L. Luckenbaugh D. A. Brutsche N. . (2014). Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 16, 119–128. doi: 10.1111/bdi.1211824103187 Nugent A. C. Robinson S. E. Coppola R. Zarate C. A. Jr. (2016). Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Res. 254, 56–66. doi: 10.1016/j.pscychresns.2016.06.00627362845 Ohnesorge H. Feng Z. Zitta K. Steinfath M. Albrecht M. Bein B. (2013). Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice. PLoS One 8:e79567. doi: 10.1371/journal.pone.007956724223972 Oliven A. O’Hearn D. J. Boudewyns A. Odeh M. De Backer W. van de P. . (2003). Upper airway response to electrical stimulation of the genioglossus in obstructive sleep apnea. J. Appl. Physiol. (1985) 95, 2023–2029. doi: 10.1152/japplphysiol.00203.200314555669 Orser B. A. Pennefather P. S. MacDonald J. F. (1997). Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86, 903–917. doi: 10.1097/00000542-199704000-000219105235 Oye I. Paulsen O. Maurset A. (1992). Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260, 1209–1213. 1312163 Pacheco D. F. Romero T. R. L. Duarte I. D. G. (2014). Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors. Brain Res. 1562, 69–75. doi: 10.1016/j.brainres.2014.03.02624675031 Pal D. Hambrecht-Wiedbusch V. S. Silverstein B. H. Mashour G. A. (2015). Electroencephalographic coherence and cortical acetylcholine during ketamine-induced unconsciousness. Br. J. Anaesth. 114, 979–989. doi: 10.1093/bja/aev09525951831 Pedraz J. L. Calvo M. B. Lanao J. M. Muriel C. Santos Lamas J. Domínguez-Gil A. (1989). Pharmacokinetics of rectal ketamine in children. Br. J. Anaesth. 63, 671–674. doi: 10.1093/bja/63.6.6712611068 Perrine S. A. Ghoddoussi F. Michaels M. S. Sheikh I. S. McKelvey G. Galloway M. P. (2014). Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS study in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 51, 9–15. doi: 10.1016/j.pnpbp.2013.11.00324246571 Perumal D. K. Adhimoolam M. Selvaraj N. Lazarus S. P. Mohammed M. A. (2015). Midazolam premedication for Ketamine-induced emergence phenomenon: a prospective observational study. J. Res. Pharm. Pract. 4, 89–93. doi: 10.4103/2279-042X.15575825984547 Petrenko A. B. Yamakura T. Fujiwara N. Askalany A. R. Baba H. Sakimura K. (2004). Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit. Anesth. Analg. 99, 1136–1140. doi: 10.1213/01.ane.0000131729.54986.3015385364 Pomarol-Clotet E. Honey G. D. Murray G. K. Corlett P. R. Absalom A. R. Lee M. . (2006). Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br. J. Psychiatry 189, 173–179. doi: 10.1192/bjp.bp.105.01526316880489 Poon T. L. Wong K. F. Chan M. Y. Fung K. W. Chu S. K. Man C. W. . (2010). Upper gastrointestinal problems in inhalational ketamine abusers. J. Dig. Dis. 11, 106–110. doi: 10.1111/j.1751-2980.2010.00424.x20402837 Reus G. Z. Abelaira H. M. dos Santos M. A. Carlessi A. S. Tomaz D. B. Neotti M. V. . (2013). Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behav. Brain Res. 256, 451–456. doi: 10.1016/j.bbr.2013.08.04124004850 Reza F. M. Zahra F. Esmaeel F. Hossein A. (2010). Preemptive analgesic effect of ketamine in patients undergoing elective cesarean section. Clin. J. Pain 26, 223–226. doi: 10.1097/AJP.0b013e3181bff86d20173436 Rodriguez C. I. Kegeles L. S. Levinson A. Ogden R. T. Mao X. Milak M. S. . (2015). In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res. 233, 141–147. doi: 10.1016/j.pscychresns.2015.06.00126104826 Rolan P. Lim S. Sunderland V. Liu Y. Molnar V. (2014). The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br. J. Clin. Pharmacol. 77, 1011–1016. doi: 10.1111/bcp.1226424977293 Sakai T. Sumikawa K. (2014). Phantom limb pain exacerbated by intravenous ketamine. J. Anesth. 28:643. doi: 10.1007/s00540-013-1752-z24292220 Salas S. Frasca M. Planchet-Barraud B. Burucoa B. Pascal M. Lapiana J. M. . (2012). Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J. Palliat. Med. 15, 287–293. doi: 10.1089/jpm.2011.035322335487 Sato Y. Kobayashi E. Hakamata Y. Kobahashi M. Wainai T. Murayama T. . (2004). Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br. J. Anaesth. 92, 859–864. doi: 10.1093/bja/aeh14415064251 Schmittner M. D. Vajkoczy S. L. Horn P. Bertsch T. Quintel M. Vajkoczy P. . (2007). Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility and need of vasopressors in patients with intracranial pathologies: a pilot study. J. Neurosurg. Anesthesiol. 19, 257–262. doi: 10.1097/ana.0b013e31811f3feb17893578 Schroeder K. E. Irwin Z. T. Gaidica M. Bentley J. N. Patil P. G. Mashour G. A. . (2016). Disruption of corticocortical information transfer during ketamine anesthesia in the primate brain. Neuroimage 134, 459–465. doi: 10.1016/j.neuroimage.2016.04.03927095309 Schwartzman R. J. Alexander G. M. Grothusen J. R. Paylor T. Reichenberger E. Perreault M. (2009). Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 147, 107–115. doi: 10.1016/j.pain.2009.08.01519783371 Sen H. Sizlan A. Yanarates O. Emirkadi H. Ozkan S. Dagli G. . (2009). A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy. Anesth. Analg. 109, 1645–1650. doi: 10.1213/ANE.0b013e3181b65ea019843803 Shanthanna H. Huilgol M. Manivackam V. K. (2010). Early and effective use of ketamine for treatment of phantom limb pain. Indian J. Anaesth. 54, 157–159. doi: 10.4103/0019-5049.6363220661356 Shaprio H. M. Wyte S. R. Harris A. B. (1972). Ketamine anaesthesia in patients with intracranial pathology. Br. J. Anaesth. 44, 1200–1204. doi: 10.1093/bja/44.11.12004647115 Sigtermans M. J. van Hilten J. J. Bauer M. C. Arbous M. S. Marinus J. Sarton E. Y. . (2009). Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 145, 304–311. doi: 10.1016/j.pain.2009.06.02319604642 Sleigh J. Harvey M. Voss L. Denny B. (2014). Ketamine–More mechanisms of action than just NMDA blockade. Trends Anaesth. Crit. Care 4, 76–81. doi: 10.1016/j.tacc.2014.03.002 Smith D. J. Bouchal R. L. DeSanctis C. A. Monroe P. J. Amedro J. B. Perrotti J. M. . (1987). Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 26, 1253–1260. doi: 10.1016/0028-3908(87)90084-02823161 Strayer R. J. Nelson L. S. (2008). Adverse events associated with ketamine for procedural sedation in adults. Am. J. Emerg. Med. 26, 985–1028. doi: 10.1016/j.ajem.2007.12.00519091264 Suppa E. Valente A. Catarci S. Zanfini B. A. Draisci G. (2012). A study of low-dose S-ketamine infusion as “preventive” pain treatment for cesarean section with spinal anesthesia: benefits and side effects. Minerva Anestesiol. 78, 774–781. 22374377 Sveticic G. Farzanegan F. Zmoos P. Zmoos S. Eichenberger U. Curatolo M. (2008). Is the combination of morphine with ketamine better than morphine alone for postoperative intravenous patient-controlled analgesia? Anesth. Analg. 106, 287–293. doi: 10.1213/01.ane.0000289637.11065.8f18165592 Tan S. Rudd J. A. Yew D. T. (2011). Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice. PLoS One 6:e21328. doi: 10.1371/journal.pone.002132821712993 Tarumi Y. Watanabe S. Bruera E. Ishitani K. (2000). High-dose ketamine in the management of cancer-related neuropathic pain. J. Pain Symptom Manage. 19, 405–407. doi: 10.1016/s0885-3924(00)00157-310991642 Thomson A. M. West D. C. Lodge D. (1985). An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313, 479–481. doi: 10.1038/313479a02982106 Traber D. L. Wilson R. D. Priano L. L. (1968). Differentiation of the cardiovascular effects of CI-581. Anesth. Analg. 47, 769–778. doi: 10.1213/00000539-196811000-000255749340 Traber D. L. Wilson R. D. Priano L. L. (1970). Blockade of the hypertensive response to ketamine. Anesth. Analg. 49, 420–426. doi: 10.1213/00000539-197005000-000225534417 Tsai T.-H. Cha T.-L. Lin C.-M. Tsao C.-W. Tang S.-H. Chuang F.-P. . (2009). Ketamine-associated bladder dysfunction. Int. J. Urol. 16, 826–829. doi: 10.1111/j.1442-2042.2009.02361.x19659678 Wang X. Ding X. Tong Y. Zong J. Zhao X. Ren H. . (2014). Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials. J. Anesth. 28, 821–827. doi: 10.1007/s00540-014-1845-324859931 Waxman K. Shoemaker W. C. Lippmann M. (1980). Cardiovascular effects of anesthetic induction with ketamine. Anesth. Analg. 59, 355–358. doi: 10.1213/00000539-198005000-000077189381 Webb A. R. Skinner B. S. Leong S. Kolawole H. Crofts T. Taverner M. . (2007). The addition of a small-dose ketamine infusion to tramadol for postoperative analgesia: a double-blinded, placebo-controlled, randomized trial after abdominal surgery. Anesth. Analg. 104, 912–917. doi: 10.1213/01.ane.0000256961.01813.da17377106 Weber F. Wulf H. Gruber M. Biallas R. (2004). S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. Paediatr. Anaesth. 14, 983–988. doi: 10.1111/j.1460-9592.2004.01358.x15601346 Weiner A. L. Vieira L. McKay C. A. Bayer M. J. (2000). Ketamine abusers presenting to the emergency department: a case series. J. Emerg. Med. 18, 447–451. doi: 10.1016/s0736-4679(00)00162-110802423 White P. F. Ham J. Way W. L. Trevor A. J. (1980). Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52, 231–239. doi: 10.1097/00000542-198003000-000086989292 White P. F. Schuttler J. Shafer A. Stanski D. R. Horai Y. Trevor A. J. (1985). Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br. J. Anaesth. 57, 197–203. doi: 10.1093/bja/57.2.1973970799 Wieber J. Gugler R. Hengstmann J. H. Dengler H. J. (1975). Pharmacokinetics of ketamine in man. Anaesthesist 24, 260–263. 1155748 Willman E. V. Andolfatto G. (2007). A prospective evaluation of “ketofol” (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. Ann. Emerg. Med. 49, 23–30. doi: 10.1016/j.annemergmed.2006.08.00217059854 Wolff K. Winstock A. R. (2006). Ketamine : from medicine to misuse. CNS Drugs 20, 199–218. doi: 10.2165/00023210-200620030-0000316529526 Wong J. J. O’Daly O. Mehta M. A. Young A. H. Stone J. M. (2016). Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression? PeerJ 4:e1710. doi: 10.7717/peerj.171026925332 Wong G. L. Tam Y. H. Ng C. F. Chan A. W. Choi P. C. Chu W. C. . (2014). Liver injury is common among chronic abusers of ketamine. Clin. Gastroenterol. Hepatol. 12, 1759.e1–1762.e1. doi: 10.1016/j.cgh.2014.01.04124534547 Wyte S. R. Shapiro H. M. Turner P. Harris A. B. (1972). Ketamine-induced intracranial hypertension. Anesthesiology 36, 174–176. doi: 10.1097/00000542-197202000-000215059108 Yamakage M. Hirshman C. A. Croxton T. L. (1995). Inhibitory effects of thiopental, ketamine and propofol on voltage-dependent Ca2+ channels in porcine tracheal smooth muscle cells. Anesthesiology 83, 1274–1282. doi: 10.1097/00000542-199512000-000188533920 Yamakura T. Chavez-Noriega L. E. Harris R. A. (2000). Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 92, 1144–1153. doi: 10.1097/00000542-200004000-0003310754635 Yamamura T. Harada K. Okamura A. Kemmotsu O. (1990). Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology 72, 704–710. doi: 10.1097/00000542-199004000-000211969718 Yanagihara Y. Ohtani M. Kariya S. Uchino K. Hiraishi T. Ashizawa N. . (2003). Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm. Drug Dispos. 24, 37–43. doi: 10.1002/bdd.33612516077 Yang C. Hu Y. M. Zhou Z. Q. Zhang G. F. Yang J. J. (2013). Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups. J. Med. Sci. 118, 3–8. doi: 10.3109/03009734.2012.72411822970723 Yang C. Y. Wong C. S. Chang J. Y. Ho S. T. (1996). Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can. J. Anaesth. 43, 379–383. doi: 10.1007/bf030117188697554 Yeaman F. Meek R. Egerton-Warburton D. Rosengarten P. Graudins A. (2014). Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. Emerg. Med. Australas 26, 237–242. doi: 10.1111/1742-6723.1217324712757 Yeom J. H. Chon M. S. Jeon W. J. Shim J. H. (2012). Peri-operative ketamine with the ambulatory elastometric infusion pump as an adjuvant to manage acute postoperative pain after spinal fusion in adults: a prospective randomized trial. Korean J. Anesthesiol. 63, 54–58. doi: 10.4097/kjae.2012.63.1.5422870366 Yu W. L. Cho C. C. Lung P. F. Hung E. H. Hui J. W. Chau H. H. . (2014). Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdom. Imaging 39, 1241–1246. doi: 10.1007/s00261-014-0173-224934474 Zakine J. Samarcq D. Lorne E. Moubarak M. Montravers P. Beloucif S. . (2008). Postoperative ketamine administration decreases morphine consumption in major abdominal surgery: a prospective, randomized, double-blind, controlled study. Anesth. Analg. 106, 1856–1861. doi: 10.1213/ane.0b013e318173277618499623 Zanos P. Moaddel R. Morris P. J. Georgiou P. Fischell J. Elmer G. I. . (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481–486. doi: 10.1038/nature1799827144355 Zarate C. A. Jr. Singh J. B. Carlson P. J. Brutsche N. E. Ameli R. Luckenbaugh D. A. . (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864. doi: 10.1001/archpsyc.63.8.85616894061 Zhang J. C. Li S. X. Hashimoto K. (2014). R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol. Biochem. Behav. 116, 137–141. doi: 10.1016/j.pbb.2013.11.03324316345 Zhou C. Douglas J. E. Kumar N. N. Shu S. Bayliss D. A. Chen X. (2013). Forebrain HCN1 channels contribute to hypnotic actions of ketamine. Anesthesiology 118, 785–795. doi: 10.1097/ALN.0b013e318287b7c823377220 Zhou C. Liang P. Liu J. Ke B. Wang X. Li F. . (2015). HCN1 channels contribute to the effects of amnesia and hypnosis but not immobility of volatile anesthetics. Anesth. Analg. 121, 661–666. doi: 10.1213/ANE.000000000000083026287296 Zhou J. Shaw S. G. Gilleece Y. (2013). Dilated common bile duct and deranged liver function tests associated with ketamine use in two HIV-positive MSM. Int. J. STD AIDS 24, 667–669. doi: 10.1177/095646241347989423970577 Zigman D. Blier P. (2013). Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. J. Clin. Psychopharmacol. 33, 270–272. doi: 10.1097/JCP.0b013e318285686523422387 Zsigmond E. K. Matsuki A. Kothary S. P. Jallad M. (1976). Arterial hypoxemia caused by intravenous ketamine. Anesth. Analg. 55, 311–314. doi: 10.1213/00000539-197605000-000055920